TAU partners with pharma company to develop COVID-19 vaccine

Written on |

The epitope-based vaccine will target the most vulnerable part of the viral spike protein

Ramot, Tel Aviv University’s technology transfer company, and Neovii, a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license agreement to develop a novel and potentially life-saving COVID-19 vaccine. Neovii will work in close collaboration with a team of scientists led by Prof. Jonathan Gershoni of TAU’s School of Molecular Cell Biology and Biotechnology.

The agreement grants Neovii the exclusive right to develop and commercialize a novel and recently patented platform technology conceived by Prof. Gershoni for the rapid discovery of epitope-based vaccines. The collaboration is focused on the development of a first-in-class COVID-19 vaccine that reconstructs the coronavirus’s Receptor Binding Motif (RBM), a critical structure of its “spike” protein. The “spike” protein itself is the major surface protein that the virus uses to bind to the cellular receptor that acts as the doorway into the human cell. After the spike protein binds to the human cell receptor, the viral membrane fuses with the cell membrane, allowing the genome of the virus  to enter the cell and begin infection.

“We have been working on coronaviruses for the last 15 years developing a method of reconstructing and reconstituting the RBM structure of the spike protein in SARS-CoV and subsequently in MERS-CoV,” explains Prof. Gershoni. “The moment the genome of the new virus was published in early January 2020, we began the process of reconstituting the RBM of SARS-CoV-2, the virus that causes COVID-19, and expect to have a reconstituted RBM of the new virus soon. This is the basis for the new vaccine, which could be ready for use within a year to a year and a half.”

Targeting the Achilles’ heel of coronavirus

“The smaller the target and the focus of the attack, the safer and greater the effectiveness of the vaccine,” he adds. “The virus takes far-reaching measures to hide its RBM from the human immune system, but the best way to ‘win the war’ is to develop a vaccine that specifically targets the virus’s RBM.” Keren Primor Cohen, Ramot CEO says: “We hope that through this collaboration with Neovii, it will be possible to produce an effective vaccine that targets the coronavirus’s Achilles’ heel and will accelerate the development of a protective vaccine against this global threat.”

Jürgen Pohle, Neovii CEO, adds: “The outbreak of the COVID-19 pandemic has demonstrated how fragile and vulnerable our societies are in the face of a pandemic.  We are extremely excited about our collaboration with Professor Gershoni and TAU which provides Neovii with a first-in-class platform for the rapid development of promising vaccine candidates towards any future emerging pandemics including COVID-19. Furthermore, the COVID-19 vaccine is highly synergistic to Neovii’s core expertise in the development and manufacturing of passive polyclonal antibodies and provides an opportunity to bring a COVID-19 immunotherapy in a rapid manner.”

Neovii’s long-standing and well-established experience and capabilities in developing, manufacturing and commercializing biopharmaceuticals will support the objective to have a vaccine ready for use in the general population on an accelerated timeline.

related posts

COVID-19 Immunity Varies Among Genders and Age Groups

July 25, 2021

New study found differences between women and men in the level of COVID-19 antibodies

July 15, 2021

First-of-its-kind study: Researchers used smart watches to monitor changes in quality of life during lockdowns

June 8, 2021

How Will We Brave the Post-COVID Era?

May 31, 2021

British Variant 45% More Contagious than Original Virus

April 28, 2021

COVID-19 Vaccinations at TAU

March 24, 2021

Covid-19 Vaccination of Nursing Mothers May Protect Babies

March 24, 2021

Academic First Responders

January 14, 2021

TAU Study Proves that Light Can Kill Coronavirus

December 14, 2020

COVID-19 Takes TAU’s Legal Clinics into High Gear

December 7, 2020

Parents show love less during COVID-19: TAU Study

December 2, 2020

Study: Women Suffer More from COVID-related Orofacial Pain

November 12, 2020

Global First: Center for Combating Pandemics

October 22, 2020

TAU Researchers Discover Antibody Combo that Fights COVID-19

October 12, 2020

Immunity Memory Cells Stay Stable Over Time After Recovery From COVID-19

October 12, 2020

Google Awards Competitive Grant to Tel Aviv University for COVID-19 Research

September 15, 2020

TAU Joint Study: COVID-19 Deaths Dive on Weekends

September 10, 2020

TAU Wins 3M Grant to Accelerate COVID-19 Vaccine Development

September 9, 2020

TAU Inaugurates Shmunis School of Biomedicine and Cancer Research

September 8, 2020

New school for Biomedicine and Cancer Research at Tel Aviv University

August 13, 2020

TAU Researcher Invents Environmentally-Friendly Sanitizer

August 11, 2020

TAU Researcher Fights Epidemics Both Viral and Virtual

July 23, 2020

Tel Aviv University presents an analysis of the reaction of human antibodies to the coronavirus

July 5, 2020

TAU Researchers Fighting Covid-19

June 30, 2020

Tel Aviv University’s Serological tests

May 25, 2020

New TAU study tracks coronavirus spread patterns in Israel

May 21, 2020

Coronavirus bootcamp? New serological test conducted with the IDF

May 19, 2020

What about the environment?

May 11, 2020

A world first: TAU to establish multidisciplinary Epidemic Research Center

May 11, 2020

Tel Aviv University joins national Coronavirus testing system

May 7, 2020

TAU lab identifies effective antibodies from recovered Coronavirus patients

May 7, 2020

TAU Student, COVID-19 Sprint Invent Disposable Ventilators to Help Treat Coronavirus Patients

April 28, 2020

TAU to partner with InnoCan Pharma on revolutionary COVID-19 treatment

April 21, 2020

TAU Scientist Awarded U.S. Patent for Novel Coronavirus Vaccine Design

April 19, 2020

Message from Tel Aviv University President

April 18, 2020

Donated Equipment Aids in Urgent Coronavirus Research

April 6, 2020

Tel Aviv University Sets Up Emergency Lab to Expand COVID-19 Testing

April 5, 2020

Milner Foundation Donates $3 million to Tel Aviv University, Magen David Adom and Tel Aviv Sourasky Medical Center (Ichilov)

March 25, 2020

Students Volunteer to Increase and Improve Coronavirus Testing Across Israel

March 22, 2020

Les étudiants de l’Université de Tel-Aviv participent au combat contre le Coronavirus

March 22, 2020

TAU researcher launches urgent push to beat corona

March 18, 2020

What’s more important? Privacy vs. public health

March 17, 2020
Ontario and Western Canada

3130 Bathurst Street, Suite, 214, Toronto, ON | M6A 2A1 
Phone: 416.787.9930 | Toll Free: 833.32.CFTAU (22328)
Email: toronto@cftau.ca

Ottawa, Quebec and Atlantic Canada

6900 Boulevard Décarie, Suite 3480, Montreal, QC | H3X 2T8
Phone: 514.344.3417
Email: montreal@cftau.ca


© CFTAU  | all rights reserved
Charitable registration: 124035643RR0001

TO TOP